Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for ABEO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -17.50M
March 31, 2026 -19.80M
December 31, 2025 -17.95M
September 30, 2025 -21.19M
June 30, 2025 -18.78M
March 31, 2025 -18.40M
December 31, 2024 -16.56M
September 30, 2024 -12.23M
June 30, 2024 -12.68M
March 31, 2024 -14.54M
December 31, 2023 -9.385M
September 30, 2023 -5.746M
June 30, 2023 -10.28M
March 31, 2023 -11.74M
December 31, 2022 -13.99M
September 30, 2022 -6.791M
June 30, 2022 -9.013M
March 31, 2022 -13.69M
December 31, 2021 -30.26M
September 30, 2021 -10.33M
June 30, 2021 -11.49M
March 31, 2021 -13.58M
December 31, 2020 -1.61M
September 30, 2020 -10.70M
June 30, 2020 -9.475M
Date Value
March 31, 2020 -13.23M
December 31, 2019 -14.25M
September 30, 2019 -18.25M
June 30, 2019 -15.24M
March 31, 2019 -15.08M
December 31, 2018
September 30, 2018 -9.04M
June 30, 2018 -9.022M
March 31, 2018 -4.082M
December 31, 2017 -5.326M
September 30, 2017 -6.77M
June 30, 2017 -4.982M
March 31, 2017 -5.857M
December 31, 2016 -3.393M
September 30, 2016 -3.989M
June 30, 2016 -3.116M
March 31, 2016 -2.516M
December 31, 2015 -2.877M
September 30, 2015 -2.512M
June 30, 2015 -1.871M
March 31, 2015 -3.163M
December 31, 2014 -1.102M
September 30, 2014 -0.14M
June 30, 2014 -0.244M
March 31, 2014 -0.125M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Corcept Therapeutics, Inc. 33.54M
Forum Markets, Inc. -12.44M
ACADIA Pharmaceuticals, Inc. 100.78M
Alnylam Pharmaceuticals, Inc. 326.72M
Anika Therapeutics, Inc. -0.684M